Nanovibronix (NASDAQ:FEED) Cut to “Sell” at Wall Street Zen

Nanovibronix (NASDAQ:FEED) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Sunday.

Separately, Weiss Ratings initiated coverage on shares of Nanovibronix in a research report on Tuesday, January 27th. They set a “sell (e+)” rating on the stock. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Nanovibronix has an average rating of “Sell”.

Nanovibronix Stock Performance

Shares of NASDAQ:FEED opened at $1.66 on Friday. The business’s 50 day simple moving average is $2.21. Nanovibronix has a one year low of $0.99 and a one year high of $88.20. The firm has a market cap of $1.81 million, a PE ratio of -0.04 and a beta of 2.09.

Insider Buying and Selling at Nanovibronix

In related news, major shareholder Christian Michael Glibert acquired 240,000 shares of the stock in a transaction dated Wednesday, January 14th. The stock was bought at an average price of $2.67 per share, for a total transaction of $640,800.00. Following the purchase, the insider directly owned 240,000 shares of the company’s stock, valued at $640,800. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.40% of the stock is owned by corporate insiders.

Nanovibronix Company Profile

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.